Skip to content
#UnblindingResearch Session Eleven Medication Trials episode artwork

Jan 16, 2019 23 min

#UnblindingResearch Session Eleven Medication Trials

from Take Aurally Hosted by Take Aurally

This is the live recording of the eleventh #UnblindingResearch session on 'Medication Trials' The blog entry containing the slides, #TakeVisually and more info can be found at https://www.takeaurally.com/new-blog-1/2018/12/21/session-eleven-medication-trials You can subscribe to Take Aurally on Apple Podcasts and SoundCloud We're now on Spotify and Instagram too! Remember you can find Take Aurally and NUH DREEAM on both Facebook and Twitter The amazing DREEAM Research Team can be found on both Facebook and Twitter Our next #UnblindingResearch session will be on Validity, Reliability and Generalisability, Bias and Confounding Variables on 20th February 2019 Our next episode is coming this Friday on Gastrointestinal History Taking! We'll be back in 2019!

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

#UnblindingResearch Session Eleven Medication Trials

0:00 23:57
of matches

Transcript Auto-generated, may contain errors

Cool, hello everyone. So this session we're going to talk about medication trials. What do you guys know about medication trials before we start? Matt knows that they involve medications. And Meg's already told me that they sometimes involve a CMO, that's good. What else do you guys know about medication trials? They have different phases. They do have different phases and we're going to explore that, good.

Not all trials that include medications would be CTs, do they? Because it depends what you're looking at. You might not be looking at the drug, for instance, you might be looking at the ways given, so it wouldn't actually be classed as a... So that's very important. So some drugs come in and out of fashion and you find that what they were originally used for... Good, good, good. I think it's the news when you've got six men in ITU. Have you seen my science? No. That's the only thing I remember about it.

It's like you guys have read my slides! today and then all the babies came out. This is all really good, can you save it for that? Otherwise the editing is only gone better. Well, otherwise, I was like, yeah, this is over now. Anyway, excellent, okay. Although this is a nice friendly environment where we can all talk together and hold hands and look at the sunset and all that, so, but please do it in the order. That's what we could turn the shape into at the top. I think this, if they were in purple, I think this is dream, personally. We could probably do that. We could do it, I'll suggest it to Frank. Don't dream at each other.

Why do we need to do medication trials? To prove that they're safe. So, all medicines are somewhere along this road, aren't they, of risks and benefits. Whatever we do to our patients will ultimately have some sort of risk associated with it. Whether that's, I'm going to reduce your stroke risk by putting you on river Oxidam, but I'm going to make you scared every time you bump your head, or increase your risk of a nosebleed, etc, etc. Here's a really good antibiotic called gentamicin that's going to save your life, but it's going to nack your kidneys potentially in the process. There's always this, so it's always along those lines. Here's as well. That's a good point.

Can you remember a few months back when we did our ethics session, what's the first line of the Hippocratic Oath? Do no harm. Yeah, primum non nocere, as they say in Latin. First, do no harm. So the first thing we've all got to do is approach our patients to make sure we're not doing it. And actually what we're doing works, which is why we are doctors and nurses and we are not homeopathic fraudsters. Have you all seen the Mitchell and Webb bit about homeopathic A&E?

It's only like a two-minute clip, it's brilliant. The guy's been run over by a bus, grab a bit of that bus, water it down, water it down, water it down, water it down, and give that to him. And it's just things like that. His lifeline's very short, that's extended, all controversial. It's brilliant, absolutely brilliant, sums up the whole homeopathic industry. Excellent. So somebody mentioned this drug, what's the drug? Thalidomide. Thalidomide. So this thing is the most famous example of the medication that went wrong. Why was thalidomide, what was its original purpose? Antisickness. Antisickness. And did it work? Yes. It worked brilliantly. What was the problem with thalidomide?

yeah so it is a chiral drug so there's a drug that's left hand and a right hand so it has two different isomers basically two different ways the molecules are arranged one way is completely safe and brilliant the other way makes your children go like this and there was no way of knowing when we were giving women the drug how much proportion of which way around the drug was so women were having great benefits not having morning sickness which is horrible we've all seen people being hospitalized like the Duchess of Cambridge used to be hospitalized at a time with her pregnancies but then obviously there's a whole generation of children born with horrendous limb deformities like this one The problem with it was that it wasn't just so GPs were prescribed to one moment but then that one was going to her mum friends and giving her mum friends the same drug so there was a linkage to how many children were born and how many prescriptions were given because it was just handed out because it was amazing.

But it's interesting, it's another example of a drug coming in, because obviously it's lidamide who's completely stopped, whereas now it's been shown to have really good benefits with certain cancers and leprosy, because it does work, you know, obviously it's a lot like a lot of medications that we take, you absolutely cannot become pregnant while you're on it, but it has some other good benefits as well. So it's a classic example that's really needed to be safe, and why there are so many phases of medication trials. Most drugs are just, well, you'll have to prove that you're either sterilised or you're on effective contraception. Yes, absolutely. Absolutely. Looks like our patients with epilepsy have to make sure if there are certain drugs that don't.

But for the man as well. If you're going to be a man in a drug study, you can't be... So the elephant man trial as it's now been known as, so we've mentioned this one, so this was a monoclonal antibody study that I can't remember which phase of study they were at but it was volunteers and it wasn't a very large group of them but apparently within an hour of being given the medication they felt like they were on fire, their face and hands were swelling up, their airways were occluding, their blood pressure was through the roof.

Some of them lost limbs or bits of limbs because they became necrotic and dropped off. I'm not sure, were there deaths? I can't remember. But they ended up on ITU. Massive organ failure, liver, kidney, lung failure, ending up on ITU. And as you can see, an otherwise completely healthy young man, perfect for a volunteer, went through this. And obviously made big headline news. But again, illustrates the need of why we need to do medication.

No, they gave them all the active drug at the exact same time. No, but was there not others there that saw what was happening to them then? Yes, so there was a degree of hysteria, there was a degree of mass hysteria with people going, oh my god, but this happened to all these things, so A&E's in Salisbury area had a mass influx of people going, I'm feeling really ill, itchy, and I'm short of breath, and there was everybody thinking, you've had Novichok poisoning, and no, it was actually a case of mass hysteria. But yeah, so this case absolutely sums up why we need to have medication for Oscar's Prize, and it's like Amy said, there were animal studies and everything, and it's all going brilliantly, and I think this is a really good drug that we could use, and then this happened, so it shows the need. And Megan's already spoken about placebo, so while we want to make sure that it's safe, we also want to make sure that it works. If you give a patient a sugar pill, they will feel better. You know, that is a well-known fact. Do you know what placebo means? I don't know, it's a Latin word. It's his band. So it's Latin for I will please.

Which I think is quite nice. That's where it came from. So you can see where doctors back in the day, especially when there was a lot of money involved, like, I will tease. Here is a completely pointless pill. What is its definition? What is a natural placebo, though? Something that mimics. The look and test of. Not necessarily mimics. Because a good placebo will look. A rubbish placebo. Yeah. But also, if you don't know what the acting one looks like.

So essentially it's any intervention that you know will not work. That's essentially a placebo. So you might do a trial of one drug that you know works versus another drug that you think might work and you're comparing that's not a placebo. A placebo is this is just sugary water. It will have no benefit to your condition whatsoever. But the reason why we do use placebos rather than doing nothing is that if a patient is getting something they will feel better. So it's known as the placebo response. And that can be a nice warm feeling that I feel better.

versus actually having a physiological response. If a patient is given a placebo and they think it will lower their blood pressure, it lowers their blood pressure. Well known and documented. And we've already talked about that trial with patients with back pain. It's in the Nature magazine of patients having this amazing response and being able to walk again having been given a placebo. And even when they're told that it's a placebo, they carry on wanting it. It's brilliant. IV placebo will work better than a tablet placebo.

And different colours have different benefits. So red is a good placebo colour. In Italy, where their royal colour is blue, a blue pill in Italy will work better than a non-blue pill. Well, that depends on the blue pill. Not the blue pills you find in a vending machine. So that's the placebo response. The amount of a response versus if you had nothing, that's what's known as the placebo effect, in case this is well documented. Most patients will regret the mean, diseases get better.

So we need to make sure that actually what we're doing is the benefit of the medicine rather than just simple chances. Cool. So this brings us on to our tabletop exercise. In the table in front of you there is an envelope, a brown envelope. And there are various stages of a trial that I've cut out. What I'd like you to do is in your groups try and arrange them into order, into what I think the order of a medication trial would be.

So what have you guys got as your top? Non-human testing to gather information about pharmacokinetics and possible toxicity. Non-human testing to gather information about pharmacokinetics and possible toxicity, brilliant. Is there any particular order that they would test the non-human testing on? So they do it on mice, their rats, their dogs. They do it on cells these days. On cells? So they eat females anymore.

So they might use mice. They might use mice, but that's a very early stage. That's actually not usually included in the phases of a trial. So this is checking through the literature, having a look at what's known about these particular drugs, seeing what's done in lab studies on cells or on something such as a mouse. But it's an idea of having, you know, looking and having an idea of how our drug works, what receptors it works on, et cetera, et cetera, et cetera. Brilliant. Because in the village I used to live in, we used to have a animal testing site. Just come off the side of the village. Really? And we used to have loads of protests. Yeah.

There's usually one opposite the QMC's and people press lab codes and hold that sign. They sit on the other side, so these are for the animals, they stand on the side of the 852 with signs and they've got blood on their lab codes. So what's the next one? Testing the pharmacokinetics of the drug in humans, it's half-life and metabolism. Brilliant, yeah. So this is what's usually known as phase zero. So this might be giving really small doses of a drug. So say you're interested in the thyroid gland. This is you giving really tiny, just little doses of the drug. You're going to have no impact whatsoever. It's about testing its half-life. How is it metabolized? You know, things like that, just to give us a little bit more information. How many people do you think you're going to need for that sort of stage? Yeah, 10, if that. So a very small group of healthy individuals who aren't on very many other medications, just to have an idea of, you know, our new drug and how it works.

and how it's metabolized, etc. Cool! What did you guys have in there? What did you put in there? Testing the drug in ideal conditions to see if it has a therapeutic effect.

So phase one is about testing your dose ranges at hand. So this isn't particularly clear, because actually, we have a study running at the minute which is looking at doses of ranges in amoxicillin, so it comes right at the end. So if people put it at the end, I think they should get a point for that. I don't want this to turn into an argument. I'm really sorry guys. Double food next time. So phase one is all about you get another small group of volunteers and give one small dose to one, double it for another, give a bigger dose and a bigger dose. It's about testing the dose ranges of your drug. Again you've got a small group of healthy volunteers and it's just an idea of seeing where's the dose range going to be, where's the therapeutic window for this drug in our patients because you start at a very early stage. So that's what phase one is broadly speaking all about.

What do you guys have next before phase two? Oh, that's the caffeine in phase three. Ideal conditions. Ideal conditions, brilliant, absolutely. So this is where you've got your group of patients who will have the specific condition that you're interested in, so say cancer studies, say a patient with thyroid problems, and you're going to test the drug usually in a centre or somewhere that you're going to be able to guarantee has ideal conditions.

Say that your new drug requires weekly blood tests. This is where you can guarantee that your patients on that medication are getting a weekly blood test to assess their dose, assess their response to the medication as well. And phase two is interested in this word that we call efficacy of the drug. The efficacy of the drug. How does that drug work in ideal conditions where you know that you're getting it at the right time every day and you're getting the right level of monitoring all the time. So you're in a larger number of people. A few hundred patients are in this stage. And you know they're getting good monitoring and they're getting everything recorded. So that probably leads on to the next one, which you'd probably want to be put to the next one.

testing in real-world conditions, absolutely. So now we're into a few thousand patients out in the real world at their GP practice in hospital, and we're assessing actually what happens to that drug in the real world. And this is where you might find that bit of conflict, that it's absolutely fine having a weekly blood test when you've got a small number of people and they're in a specialist unit, but what is it actually like in a GP practice having to bring our new patients in with their thyroid and have their TFTs checked every week, and you might find that there's some conflict there. And this is what's known as the effectiveness of the drug. So phase two is about the efficacy, phase three is about the effectiveness.

Phase two and phase three are where the vast majority of trials are at. And so that's where a lot of the trials that we're seeing are about the efficacy and the effectiveness of the medication. Because it may well be that there's a new drug that's great in trauma, but then you need to have hourly sequential blood tests after it. That might be great in a lab, absolutely fantastic, but then how does that actually work in a major trauma centre that is the busiest day in Europe, such as ours? So that's really useful information for everybody. So finally, you've got...

Widespread use. Monitoring widespread use. So this is what's known as phase four. So this is where the drug has a license. We've found it to be safe. We know the dose range has got an indication. Go forth and use it. But this is about monitoring in the community. It's widespread use to see what happens. And then is there a reporting of patients 10 years after taking this medication presenting with pulmonary disease, for example. Is there a cohort of women who take this disease coming in reporting birth defects, et cetera, things like that. So this is all about that. Or is it patients on this drug, once they start taking another one, is there an interaction we haven't come across?

In the UK, it's the MHRA. They're responsible for the safety of the medications and devices that's in this country. So they are responsible for all the equipment and all the drugs that we use. And they are the ones that are involved in place for monitoring. Do you know how we can report things if we suspect an effect? Yellow cards. Yellow cards, yeah. So if you're ever looking at BNF, you'll find this yellow card system. And it's a way of reporting. There is...

a website as well, and there's even an app, apparently, so that you can report any of the effects that you come across. So if you think that your patient has had an effect due to whatever we've done, we can report it, and they can go, OK, we agree, or no. Is there part of a drug study, though? You wouldn't do it for me on a card? No. No. But this is all technically still. Phase 4 is still monitoring about it. Phase 4 is a continuous thing. It doesn't end ever. It doesn't end ever. It doesn't end ever. We are still checking to see what happens with every drug, pretty much. So did you ever officially 100% say that a drug wouldn't be safe to use? Technically, no.

Because we always have to assume that there could be something. So, you know, and drugs change uses. So, for example, we started putting people on low-dose aspirin, which we weren't doing, now people are on low-dose aspirin. That needs to be, well, so what's the long-term benefit? Is there any impact on that? So, you know, because as I said, drugs come in and out of fashion, we use it for different things. We are now starting to give patients thalidomide again. So we know about some effects that that has, obviously, but are there any others that can come across? So say you're in a lab and you created a brand new drug.

How long is it realistically going to take for that, when you're first going to initially create it, when it becomes available? Sixty years. Sixty. It's a long time. What about if you're using a already produced drug for a different reason? We'll probably be going on six years.

Is it a shorter time? It's a shorter time, especially if your indication, so if your drug is indicated for one thing and you think of another thing that is related, i.e. another sort of bleeding, that is a shorter period of time. But if it is a drug, say thalidomide, that's been used for morning sickness and wanted to use it for leprosy, that is a bit of a bigger jump. So there's no hard and fast rule, but it is out there. It's years and years and years. Cancer Research UK have a really good page about phases and trials, where if I'm giving that a read. So obviously a lot of patients who have cancer are on some sort of trials, so there's lots of really good information aimed at which includes.

And I really recommend reading The Nature. It was in September 2018, their article they published about the placebo trial with patients with back pain. It's really, really interesting. There was a TV program. Oh, there was a TV program granted. Cool.

So next month, we're validity, reliability, and reliability. Now we're talking about bias and confounding practice. That's going to be an abundant exception. So that's... They're all very big words, Jamie. Very big words. We'll break it down. What is happening today? What's that? And. That's the only word I know, isn't it? Such a Derby fan. Thank you. Okay, so, democratic, what's the pun for today going to be? Something about hard pill to swallow. That's what you said, isn't it? Hard pill to swallow. Brexit pill to swallow. Is it Brexit related? Is it Brexit related? Is it Brexit related?

Change it. No, I haven't got one. There literally isn't one. So it's up to you guys. Jamie, you couldn't think of one, would you? No sweets and no fun. I mean, yeah. It's not really been all like research, has it? No. And I was going to teach you about it in the next hour. It doesn't have to be a trial. I think a bit of pills to swallow. A bit of pills to swallow. Don't make it a bit of pills to swallow. Yes. Let's be positive.

Frequently asked questions

How long is this episode of Take Aurally?

This episode is 23 minutes long.

When was this Take Aurally episode published?

This episode was published on January 16, 2019.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Take Aurally episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.